Cagrilintide: The Complete Guide

What is Cagrilintide?

Here is something most people do not know about how the body handles meals: when you eat, your pancreas releases two hormones at the same time. Insulin gets all the attention — it manages blood sugar. But alongside insulin, your pancreas also releases a much less famous hormone called amylin. Amylin's job is different: it tells your brain that food has arrived. Slow down. Stop eating. The meal is handled.

Cagrilintide is a long-acting analogue of that natural amylin hormone — engineered to do what amylin does, but stable enough to last in the body. Natural amylin breaks down within minutes after release. Cagrilintide is structurally modified to resist that breakdown, giving it a duration of action long enough for once-weekly dosing.

What makes Cagrilintide interesting in the metabolic peptide story is the receptor it targets. Tirzepatide and Retatrutide work the GIP, GLP-1, and glucagon family — hormones released by the gut after meals. Cagrilintide works through an entirely different system — the amylin receptors, located primarily in a brainstem region called the area postrema. Same goal (telling the brain you are full) — completely separate pathway. Novo Nordisk — the same company behind Semaglutide (Ozempic, Wegovy) — is currently developing Cagrilintide as part of a combination programme called CagriSema, where Cagrilintide and Semaglutide are studied together. Research suggests targeting two independent fullness pathways at once produces effects neither alone can achieve. Cagrilintide is currently in late-stage clinical trials. It is not yet approved by the FDA, EMA, or TGA.

Research Applications

Research on Cagrilintide spans the amylin signalling system, comparative metabolic pharmacology, and the CagriSema combination programme — one of the most-watched research developments in the metabolic peptide field.

How Cagrilintide Works

The big-picture answer first: Cagrilintide amplifies a fullness signal your body already produces but cannot keep producing for long. Natural amylin tells the brain "food has arrived" but breaks down within minutes. Cagrilintide is the same signal in a longer-lasting form.

What amylin does naturally: when you eat, your pancreas releases insulin and amylin together. Insulin handles blood sugar. Amylin sends a different signal — a message to your brain that food has arrived. Research suggests amylin promotes satiety (the feeling of fullness), slows gastric emptying so food is absorbed more gradually, and suppresses glucagon release (which would otherwise raise blood sugar). Picture insulin as managing the sugar from the meal, and amylin as managing your appetite while the meal is being processed.

Why an analogue is needed: natural amylin is wonderfully effective but extremely short-lived. The body releases it in pulses with meals, and within minutes most of it has broken down. Research suggests Cagrilintide's structural modifications resist that rapid breakdown, providing a sustained version of the same signal. Once-weekly dosing means the body has access to amylin signalling continuously rather than in tiny pulses.

The CagriSema rationale: GLP-1 (Semaglutide) and amylin (Cagrilintide) reduce appetite through brain pathways that do not overlap. Research suggests GLP-1 works primarily through the hypothalamus and various brainstem nuclei, while amylin acts mainly on the area postrema — a brainstem region with its own appetite-modulating role. By activating both pathways simultaneously through CagriSema, researchers aim to achieve more comprehensive appetite suppression than either pathway alone. The logic is the same as Tirzepatide adding GIP to GLP-1, just executed through two molecules instead of one.

Mechanistically distinct from the GIP/GLP-1 family: this is part of why Cagrilintide is interesting. It is not another variation of the same hormone family that Tirzepatide and Retatrutide work. It targets a completely different receptor system, with completely different downstream signalling, in a different brain region. Research suggests this means Cagrilintide can be combined with GIP/GLP-1 compounds without the receptors competing for the same binding sites.

Storage Guidelines

Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.

Frequently Asked Questions

Technical Specifications

Published References

1. Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet (London, England), 2021. PubMed
   The pivotal Phase 2 trial that established Cagrilintide as a viable long-acting amylin agonist for once-weekly dosing. Important reading for understanding the original safety and efficacy data that supported Phase 3 development.
2. Enebo LB, Berthelsen KK, Kankam M, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.” Lancet (London, England), 2021. PubMed
   The first published study of the Cagrilintide + Semaglutide combination — the foundation for the entire CagriSema research programme. Established that the two compounds could be co-administered safely and that their effects appeared additive.
3. Frias JP, Deenadayalan S, Erichsen L, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” Lancet (London, England), 2023. PubMed
   A more recent CagriSema Phase 2 trial in type 2 diabetes patients. Reported greater effects on body weight and HbA1c than Semaglutide alone — the result that supported moving CagriSema into Phase 3 development.

Browse all Cagrilintide research on PubMed →